Dividends & Buybacks ·
Curanex Pharmaceuticals Inc regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price…
CURXCuranex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. The company previously received a deficiency notice on November 5, 2025, for failing to maintain a $1.00 per share closing price for 30 consecutive business days. To address this, Curanex effected a 1-for-20 reverse stock split of its common shares on August 20, 2026. On September 3, 2026, Nasdaq notified the company that its stock had closed at $1.00 or greater for the last 10 consecutive business days following the split, resolving the compliance issue. Curanex Pharmaceuticals Inc operates in the biotechnology industry and focuses on drug discovery and development.